Augustine治疗技术公司筹集77.7M欧元,用于研制一种新药,治疗Charcot-Marie-Tooth疾病。 Augustine Therapeutics raises €77.7M to develop a new drug for Charcot-Marie-Tooth disease.

Augustine治疗公司是一家生物技术公司,获得7 770万欧元的资金,由Jeito Capital和Novo控股公司领导,用于为Charcot-Marie-Tooth病提供AGT-100216药物。 Augustine Therapeutics, a biotech firm, secured €77.7 million in funding led by Jeito Capital and Novo Holdings to advance its drug AGT-100216 for Charcot-Marie-Tooth disease. 这笔资金还将支持研究其他神经退化和心血管代谢疾病的治疗方法。 The funding will also support research into treatments for other neurodegenerative and cardio-metabolic diseases. AGT-100216有选择地抑制HDAC6, 可能保留有益的非催化性功能。 AGT-100216 selectively inhibits HDAC6, potentially preserving beneficial non-catalytic functions.